Gujarat Themis Biosyn Limited — Others, 01-08-2025: Appointment

Gujarat Themis Biosyn's Board approved the financial results for the latest quarter, with net profit reaching INR 9.06 Cr and total income at INR 36.15 Cr. A record date of September 5 has been set for the dividend. The company will not proceed with its merger plans, opting to focus on its core fermentation-based pharmaceutical business. This strategic shift is supported by the new Vapi API plant commencing production in May, strengthening export capabilities. Additionally, Mr. Nihar Parikh, an entrepreneur and venture capitalist, joins the Board as an Independent Director, replacing Mr. Siddharth Kusumgar.